Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Therapy in Salivary Gland Carcinoma
NCT06145308Phase 2Recruiting
- Sponsor
- Peking Union Medical College
- Start
- Aug 2023
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, larotrectinib, entrectinib, leuprolide, bicalutamide in salivary gland carcinoma (SGC), sponsored by Peking Union Medical College. Started Aug 2023; status: recruiting.
02
Drugs
disitamab vedotinlarotrectinibentrectinibleuprolidebicalutamide
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT06145308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145308.